Busilinks Pharmaceuticals: Holding subsidiary Zhejiang Tianyuan participates in the "multifunctional antibody prophylactic HIV vaccine research and development" project.

Bo Shang Pharmaceuticals announced that its holding subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., recently received a notification from the National Health Commission's Medical and Health Technology Development Research Center on the approval of the "National Science and Technology Major Project for the Prevention and Control of New and Emerging Infectious Diseases in 2026". The project is titled "Research and Development of Multifunctional Antibody Preventive AIDS Vaccine", with Zhejiang Tianyuan's involvement in the topic of "Production of AIDS Vaccine and Phase I Clinical Declaration". The project's implementation period is from March 2026 to February 2031.